This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Shareholder Claims Against Genoptix Investigated By Goldfarb Branham LLP

Goldfarb Branham LLP is investigating whether certain officers and directors of Genoptix, Inc. (NASDAQ: GXDX) violated state and federal securities laws. Genoptix stock plummeted from $38.79 in April 2010 to $17.19 in June 2010 after the company issued a series of statements about its financial results far below consensus. Concerned shareholders are urged to contact securities lawyer Hamilton Lindley at 877-583-2855 or hlindley@goldfarbbranham.com about their rights and remedies.

“According to a class action complaint, the company failed to disclose its significant problems while touting its hematology and oncology testing and diagnostics business,” said securities lawyer Hamilton Lindley. “Those allegations also include that Genoptix failed to disclose its business model was unsustainable due to increased competition, managed care pressures, sales force effectiveness and changing trends at the physician level.”

Goldfarb Branham LLP lawyers have significant experience representing shareholders and whistleblowers in securities lawsuits nationwide. The firm may be retained without financial obligation or cost to its clients. Genoptix investors who purchased before or between June 31, 2009 and June 15, 2010, and continue to hold their shares, should contact Hamilton Lindley at hlindley@goldfarbbranham.com or 877-583-2855.

Copyright Business Wire 2010

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,573.58 +132.99 0.76%
S&P 500 2,084.55 +16.91 0.82%
NASDAQ 5,067.3410 +27.5650 0.55%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs